Across TCGA pan-cancer cohorts, ADH7 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ADH7’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ADH7 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ADH7 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and PDAC are the cancer types where ADH7 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADH7 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	−2.128	<.001	11	view →
LUAD	All	III,IV	−1.336	<.001	9	view →
PDAC	Female	II,III,IV	−1.693	<.001	8	view →
LSCC	All	II,III,IV	+1.586	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ADH7 RNA expression & survival · all ADH7 data types